Announcement • Jun 24
Fibrobiologics, Inc. Announces Non Standing for Re-Election of Stacy Coen to the Board FibroBiologics, Inc. held its Annual Meeting on June 22, 2026 announced that Stacy Coen did not stand for re-election to the Board at the Annual Meeting. Accordingly, her term as a Class III director expired at the conclusion of the Annual Meeting. Announcement • Jun 23
FibroBiologics Receives Notice Of Allowance For U S Patent Covering Topical Fibroblast Spheroid Therapy For Wound Healing FibroBiologics announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application entitled “Therapeutic Use of Fibroblasts in Wound Healing.” The allowed application, U.S. Patent Application No. 18/184,726, contains 19 allowed claims directed to methods of treating and accelerating the healing of wounds by topically administering a composition comprising three-dimensional (3D) spheroid fibroblasts together or with one or more fibroblast-derived materials. A Notice of Allowance indicates that the USPTO has completed its examination and intends to grant the patent. Some of the allowed claims include: Methods of topically administering 3D spheroid fibroblasts and fibroblast-derived materials into, adjacent to, or on the surface of a wound. Treatment of chronic wounds, and of individuals who have diabetes or cancer, or who are immunologically compromised. Treatment of wounds including cuts, abrasions, bedsores, and burns. Use of activated or manipulated 3D spheroid fibroblasts, including myofibroblasts. Methods of accelerating the healing of one or more wounds using the same compositions. The patent aligns closely with FibroBiologics’ lead wound healing program. CYWC628, the Company’s investigational topically administered allogeneic fibroblast-spheroid cell-based therapy, is currently being evaluated in a Phase 1/2 clinical trial in patients with diabetic foot ulcers, among the most common and difficult-to-treat chronic wounds. The newly allowed claims specifically encompass the topical treatment of chronic wounds and of individuals with diabetes, the precise patient population and clinical setting addressed by the CYWC628 program. The allowed claims capture a distinctive feature of the technology, which is the combination of 3D spheroid fibroblasts with or without fibroblast-derived materials such as exosomes and extracellular vesicles. The examiner specifically recognized that this combination is not taught by the prior art. That distinction is the core belief that the topical fibroblast-spheroid therapy can actively support the biology of wound repair rather than simply manage symptoms, and it provides a strong intellectual property foundation as clinical data is generated. Announcement • Jun 16
FibroBiologics, Inc. Advances Patient Dosing For Phase 1/2 Clinical Trial Of CYWC628 For The Treatment Of Diabetic Foot Ulcers FibroBiologics, Inc. announced that the first patients have been dosed in the Company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). Initial dosing took place during the week of June 1, 2026. In parallel with clinical progress, FibroBiologics continues to advance manufacturing of CYWC628 to support ongoing trial activity. Drug product from the Company's second good manufacturing practice (GMP) manufacturing run has been released and is scheduled to ship to Australia during the week of June 15, 2026. FibroBiologics has also completed the manufacturing of the first two batches of its third GMP manufacturing run. CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy for wound healing. Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments. FibroBiologics is conducting a prospective, multicenter, randomized clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 weeks of treatment using either standard of care plus a low or high-dose of CYWC628, or standard of care only. 
